Genetic study identifies FNIP1 gene as potential target for cardiometabolic diseases.

A large-scale exome sequencing study, involving over one million individuals, has identified rare protein-coding variants in the FNIP1 gene. These variants are linked to favorable fat distribution, reduced liver fat, improved glycemic control, and a significantly lower risk of cardiometabolic diseases. Published in Nature, this research highlights FNIP1 as a promising therapeutic target for common conditions like diabetes and heart disease, potentially leading to new treatment strategies.